Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros

Base de datos
Tipo del documento
Intervalo de año
1.
Diabetes Metab Syndr ; 15(4): 102196, 2021.
Artículo en Inglés | MEDLINE | ID: covidwho-1293738

RESUMEN

AIMS: Diabetes Mellitus predisposes patients to invasive fungal infections. There has been a recent surge of Mucormycosis with COVID 19 infection particularly in patients with diabetes. This study aims to study the clinical spectrum of CAM (COVID -associated Mucormycosis) with diabetes and subsequent outcomes. MATERIAL AND METHODS: This was a descriptive study conducted at a single COVID Care Centre in India in patients with COVID Associated Mucormycosis from April 12, 2021 to May 31, 2021. RESULTS: Among 953 hospitalized patients with COVID 19 infection, 32 patients had CAM with an incidence of 3.36%. In patients with CAM, 87.5% had Diabetes Mellitus as the most common co-morbidity. The majority of the patients had poor glycemic control with a mean HbA1c of 9.06%. Out of the total study population, 93% had prior exposure to high dose corticosteroids. During the study period, 12.5% patients of CAM did not survive. CONCLUSION: Mucormycosis is an angioinvasive fungal infection with high mortality. The disease has surged in COVID 19 pandemic due to uncontrolled diabetes and improper corticosteroid use.


Asunto(s)
COVID-19/complicaciones , Diabetes Mellitus/fisiopatología , Hospitalización/estadística & datos numéricos , Mucormicosis/mortalidad , SARS-CoV-2/aislamiento & purificación , COVID-19/transmisión , COVID-19/virología , Diabetes Mellitus/virología , Femenino , Humanos , India/epidemiología , Masculino , Persona de Mediana Edad , Mucormicosis/epidemiología , Mucormicosis/patología , Mucormicosis/virología , Pronóstico , Factores de Riesgo , Tasa de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA